STOCK TITAN

Kodiak Sciences Inc. - KOD STOCK NEWS

Welcome to our dedicated page for Kodiak Sciences news (Ticker: KOD), a resource for investors and traders seeking the latest updates and insights on Kodiak Sciences stock.

Kodiak Sciences Inc. (Nasdaq: KOD) pioneers retinal disease treatments through its innovative ABC Platform, merging biologics and chemistry to develop durable therapies. This page delivers verified updates on clinical advancements, financial disclosures, and strategic developments critical for stakeholders tracking ophthalmology innovation.

Access timely reports on KOD's pipeline progress, including tarcocimab trials and bispecific candidates targeting VEGF/IL-6 pathways. Our curated news collection emphasizes material events: regulatory milestones, partnership announcements, and peer-reviewed data publications shaping retinal therapeutics.

Bookmark this resource for structured updates on Kodiak's mission to reduce treatment frequency in conditions like diabetic eye disease. Regularly refreshed with press releases and analysis-neutral summaries, this page serves as your hub for monitoring one of biopharma's most compelling ocular innovators.

Rhea-AI Summary

Kodiak Sciences Inc. (Nasdaq: KOD) reported Q4 2020 financial results, revealing a net loss of $46.6 million, or $0.97 per share, up from a $15.6 million loss in Q4 2019. The company's cash position improved to $969 million, boosted by a $612 million equity offering. Phase 1b data for KSI-301 showed significant treatment durability, with two-thirds of patients achieving a 6-month treatment-free interval after three doses. Kodiak is advancing its pivotal clinical studies, including DME and RVO, with key milestones expected in 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.48%
Tags
-
Rhea-AI Summary

Kodiak Sciences Inc. (Nasdaq: KOD) announced positive one-year results from a Phase 1b study of KSI-301, an investigational therapy for retinal diseases. The data revealed that 66-69% of patients with wet age-related macular degeneration (AMD), diabetic macular edema (DME), and retinal vein occlusion (RVO) achieved a six-month treatment-free interval. Additionally, significant letter improvements were noted: 5.7 for AMD, 7.6 for DME, and 22.2 for RVO. The safety profile remains encouraging, with over 700 doses administered in the study, suggesting potential for KSI-301 as a new standard of care.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary

Kodiak Sciences Inc. (Nasdaq: KOD) announced a presentation of clinical study data on its investigational therapy KSI-301 at the Angiogenesis, Exudation, and Degeneration 2021 virtual meeting on February 13, 2021. The data from the Phase 1b study shows excellent safety and strong efficacy, with two-thirds of patients achieving a six-month treatment-free interval after only three loading doses. KSI-301 aims to improve outcomes for retinal vascular diseases such as wet AMD, diabetic macular edema, and retinal vein occlusion.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.01%
Tags
conferences clinical trial
Rhea-AI Summary

Kodiak Sciences Inc. (Nasdaq: KOD) will present at the virtual J.P. Morgan Healthcare Conference on January 11, 2021, at 11:50 a.m. Pacific Time. A live webcast can be accessed on Kodiak's website and will be available for replay after the event. The company focuses on developing therapeutics for retinal diseases using its innovative ABC Platform™. Notable products include KSI-301 for age-related macular degeneration and KSI-501 for neovascular retinal diseases. Founded in 2009 and based in Palo Alto, CA, Kodiak aims to combat global blindness causes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.13%
Tags
conferences
-
Rhea-AI Summary

Kodiak Sciences Inc. (Nasdaq: KOD) closed a public offering of 5,972,222 shares at $108.00 each, raising approximately $645.0 million. This includes an additional 778,985 shares sold after underwriters exercised their purchase option in full. The offering was managed by J.P. Morgan, Morgan Stanley, Jefferies, and Evercore ISI, under the terms of an effective shelf registration statement filed with the SEC. Kodiak focuses on developing therapeutics for high prevalence retinal diseases, with its lead candidate KSI-301 targeting retinal vascular diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.34%
Tags
-
Rhea-AI Summary

Kodiak Sciences Inc. (Nasdaq: KOD) has announced a public offering of 5,193,237 shares of common stock at $108.00 per share, aiming to raise approximately $560.9 million before expenses. The offering is set to close on or around November 20, 2020, pending customary conditions. An option for underwriters to purchase an additional 778,985 shares is also included. J.P. Morgan, Morgan Stanley, Jefferies, and Evercore ISI are the lead managers for this offering, which follows an effective shelf registration statement with the SEC.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.18%
Tags
Rhea-AI Summary

Kodiak Sciences Inc. (Nasdaq: KOD) has announced a proposed underwritten public offering of $400 million of its common stock, with underwriters granted a 30-day option to purchase an additional $60 million. The offering is subject to market conditions and may not complete as planned. J.P. Morgan, Morgan Stanley, Jefferies, and Evercore ISI are the joint book-running managers. The shares are being offered under a previously filed shelf registration statement that became effective on November 16, 2020.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.6%
Tags
-
Rhea-AI Summary

Kodiak Sciences Inc. (Nasdaq: KOD) announced the completion of patient recruitment for its DAZZLE pivotal study of KSI-301, an anti-VEGF therapy targeting wet age-related macular degeneration. The study exceeded its goal of 550 treatment-naïve patients, despite COVID-19 challenges. Top-line data is expected in early 2022. KSI-301 aims to offer a less frequent treatment regimen, potentially improving vision outcomes. Additional studies for diabetic macular edema and retinal vein occlusion are also progressing, supporting Kodiak's development objectives in retinal disease therapies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.77%
Tags
-
Rhea-AI Summary

Kodiak Sciences Inc. (Nasdaq: KOD) announced management presentations at two virtual investor conferences: the Jefferies Virtual London Healthcare Conference on November 17, 2020, at 11:20 a.m. PT, and the Evercore ISI HealthCONx Conference on December 3, 2020, at 8:20 a.m. PT. A live webcast will be available on Kodiak's website, along with replays shortly after each event. Kodiak focuses on developing therapeutics for retinal diseases, highlighted by its lead candidate, KSI-301, targeting age-related macular degeneration and diabetic eye diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.75%
Tags
conferences
Rhea-AI Summary

Kodiak Sciences (Nasdaq: KOD) presented clinical data for KSI-301 at the AAO 2020 Virtual Annual Meeting, emphasizing its long-term efficacy and safety in treating diabetic macular edema (DME). The presentation, led by Dr. Arshad M Khanani, highlighted the promising durability and efficacy of KSI-301 compared to current anti-VEGF treatments. The ongoing Phase 3 GLEAM and GLIMMER studies aim to enroll approximately 450 patients each to assess KSI-301's impact on vision correction over two years. KSI-301 is positioned to address the significant treatment burden in diabetic eye diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.2%
Tags

FAQ

What is the current stock price of Kodiak Sciences (KOD)?

The current stock price of Kodiak Sciences (KOD) is $4.21 as of April 28, 2025.

What is the market cap of Kodiak Sciences (KOD)?

The market cap of Kodiak Sciences (KOD) is approximately 171.5M.
Kodiak Sciences Inc.

Nasdaq:KOD

KOD Rankings

KOD Stock Data

171.48M
50.31M
4.65%
80.44%
4.42%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
PALO ALTO